Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations

Updated on
  • Rothschild is advising Meda; sale may start in September
  • Company may fetch about $1 billion from sale of U.S business

Swedish drugmaker Meda AB is exploring options including a sale of its U.S. operations amid a boom in health care deals, according to people with knowledge of the matter. The company’s shares jumped in Stockholm.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.